<div id="readability-page-1"><p>DAVENPORT &amp; Co LLC purchased a new stake in  Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 2,689,336 shares of the company's stock, valued at approximately $3,631,000. DAVENPORT &amp; Co LLC owned about 3.66% of Cognition Therapeutics as of its most recent filing with the SEC.</p><ul><li>November’s Small-Cap Treasures: 3 Stocks Poised for Growth</li></ul><p>Separately, Northeast Financial Consultants Inc grew its position in shares of  Cognition Therapeutics by 158.6% in the first quarter. Northeast Financial Consultants Inc now owns 63,351 shares of the company's stock valued at $27,000 after purchasing an additional 38,851 shares during the period. 43.35% of the stock is currently owned by institutional investors. </p><div><p><span></span><span>Get <strong>Cognition Therapeutics</strong> alerts:</span></p></div><h2>Cognition Therapeutics Trading Down 0.7%</h2><p>Shares of Cognition Therapeutics stock opened at $1.45 on Friday. The business's fifty day moving average price is $1.61 and its 200 day moving average price is $1.37. Cognition Therapeutics, Inc. has a twelve month low of $0.22 and a twelve month high of $3.83. The stock has a market capitalization of $127.99 million, a P/E ratio of -3.02 and a beta of 1.23. </p><p>Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01.  As a group, sell-side analysts predict that  Cognition Therapeutics, Inc. will post -0.8 EPS for the current year. </p><h2>Wall Street Analyst Weigh In</h2><p>Several equities analysts recently commented on CGTX shares. Wall Street Zen upgraded Cognition Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 8th. HC Wainwright  restated a &#34;buy&#34; rating and issued a $3.00 price target on shares of Cognition Therapeutics in a report on Thursday, December 4th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Cognition Therapeutics in a research note on Monday. Finally, B. Riley  reissued a &#34;buy&#34; rating and issued a $3.00 target price (up from $2.00) on shares of Cognition Therapeutics in a research report on Friday, November 21st. One research analyst  has rated the stock with a Strong Buy rating, three have given a Buy rating and one  has issued  a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $3.33.</p><p><b>Get Our Latest Research Report on Cognition Therapeutics</b></p><h2>Cognition Therapeutics Profile</h2> (Free Report)<p>Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer's disease. The company's lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer's disease.  </p><p>CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer's disease.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Cognition Therapeutics</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Do you know what Amazon is planning for January 1?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><strong>Want to see what other hedge funds are holding CGTX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cognition Therapeutics Right Now?</h2><p>Before you consider Cognition Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cognition Therapeutics wasn't on the list.</p><p>While Cognition Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CGTX

<p>DAVENPORT & Co LLC invested in Cognition Therapeutics, Inc., purchasing 2,689,336 shares valued at $3,631,000, owning 3.66% of the company. Cognition Therapeutics' stock opened at $1.45, with a market cap of $127.99 million. Analysts have mixed ratings, with a consensus target price of $3.33. The company focuses on Alzheimer's therapies, with its lead candidate CT1812 in Phase 2 trials.</p>

DAVENPORT & Co LLC Makes New Investment in Cognition Therapeutics, Inc. $CGTX